Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund
2023-04-01
|
| Series: | EXCLI Journal : Experimental and Clinical Sciences |
| Subjects: | |
| Online Access: | https://www.excli.de/index.php/excli/article/view/6022 |
| _version_ | 1797839982908407808 |
|---|---|
| author | Habib Yaribeygi Mina Maleki Tannaz Jamialahamdi Seyed Adel Moallem Amirhossein Sahebkar |
| author_facet | Habib Yaribeygi Mina Maleki Tannaz Jamialahamdi Seyed Adel Moallem Amirhossein Sahebkar |
| author_sort | Habib Yaribeygi |
| collection | DOAJ |
| description | Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed. |
| first_indexed | 2024-04-09T16:06:57Z |
| format | Article |
| id | doaj.art-feefe02ae57e4ec5954866486ca10428 |
| institution | Directory Open Access Journal |
| issn | 1611-2156 |
| language | English |
| last_indexed | 2024-04-09T16:06:57Z |
| publishDate | 2023-04-01 |
| publisher | IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund |
| record_format | Article |
| series | EXCLI Journal : Experimental and Clinical Sciences |
| spelling | doaj.art-feefe02ae57e4ec5954866486ca104282023-04-25T06:22:09ZengIfADo - Leibniz Research Centre for Working Environment and Human Factors, DortmundEXCLI Journal : Experimental and Clinical Sciences1611-21562023-04-012240341410.17179/excli2023-60225461Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disordersHabib Yaribeygi0https://orcid.org/0000-0002-1706-6212Mina Maleki1https://orcid.org/0000-0003-4723-3058Tannaz Jamialahamdi2https://orcid.org/0000-0001-9521-3153Seyed Adel Moallem3https://orcid.org/0000-0003-4507-2932Amirhossein Sahebkar4https://orcid.org/0000-0002-8656-1444Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. E-mail: habib.yari@yahoo.comUrology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranSurgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Pharmacology and Toxicology, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq; Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran. E-mail: amir_saheb2000@yahoo.comDiabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.https://www.excli.de/index.php/excli/article/view/6022diabetes mellitussodium-glucose cotransporter-2 inhibitorslivernon-alcoholic fatty liver disordersfibrosishepatocellular carcinomacirrhosis |
| spellingShingle | Habib Yaribeygi Mina Maleki Tannaz Jamialahamdi Seyed Adel Moallem Amirhossein Sahebkar Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders EXCLI Journal : Experimental and Clinical Sciences diabetes mellitus sodium-glucose cotransporter-2 inhibitors liver non-alcoholic fatty liver disorders fibrosis hepatocellular carcinoma cirrhosis |
| title | Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders |
| title_full | Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders |
| title_fullStr | Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders |
| title_full_unstemmed | Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders |
| title_short | Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders |
| title_sort | hepatic benefits of sodium glucose cotransporter 2 inhibitors in liver disorders |
| topic | diabetes mellitus sodium-glucose cotransporter-2 inhibitors liver non-alcoholic fatty liver disorders fibrosis hepatocellular carcinoma cirrhosis |
| url | https://www.excli.de/index.php/excli/article/view/6022 |
| work_keys_str_mv | AT habibyaribeygi hepaticbenefitsofsodiumglucosecotransporter2inhibitorsinliverdisorders AT minamaleki hepaticbenefitsofsodiumglucosecotransporter2inhibitorsinliverdisorders AT tannazjamialahamdi hepaticbenefitsofsodiumglucosecotransporter2inhibitorsinliverdisorders AT seyedadelmoallem hepaticbenefitsofsodiumglucosecotransporter2inhibitorsinliverdisorders AT amirhosseinsahebkar hepaticbenefitsofsodiumglucosecotransporter2inhibitorsinliverdisorders |